MDS Proteomics Bolsters Informatics Team with Addition of Leading Data Analysis Software Development and Mathematical Research Experts.Business Editors/Medical Writers TORONTO--(BUSINESS WIRE)--Oct. 1, 2001 NCBI NCBI National Center for Biotechnology Information (NIH) NCBI National Coalition Building Institute NCBI National Council for the Blind of Ireland (Dublin, Ireland) Staff Scientist and Maersk McKinney Moller Institute Director to Lead Company's BioInformatics Software Development and Research Components MDS MDS, n See temporomandibular pain-dysfunction syndrome. MDS 1 Maternal deprivation syndrome, see there 2 Myelodysplastic syndrome, see there Proteomics, a leading proteomics-based drug discovery company, today announced the addition of two directors, Hugues Sicotte and Peder Thusgaard Ruhoff, to its informatics team. Both executives bring key expertise to MDS Proteomics; Sicotte from his recent position as staff scientist at the National Center for Biotechnology Information The National Center for Biotechnology Information (NCBI) is part of the United States National Library of Medicine (NLM), a branch of the National Institutes of Health. The NCBI is located in Bethesda, Maryland and was founded in 1988. (NCBI) and Ruhoff from his position as director of the Maersk McKinney Moller Institute for Production Technology at the University of Southern Denmark As a national institution the University of Southern Denmark (SDU) comprises five faculties – Humanities, Science, Engineering, Social Sciences and Health Sciences totaling 32 departments, 11 research centers and a university library. . Sicotte and Ruhoff will drive the company's bioinformatics software development and informatics research arms, respectively, key to the company's efforts in speeding the development of new medicines. Sicotte and Ruhoff join the company's growing informatics division, currently with more than 45 employees. As director of the company's Toronto-based bioinformatics team, Sicotte will be responsible for the overall development of MDS Proteomics' bioinformatics and supercomputing software platform used to analyze the enormous volume of protein expression and molecular interactions data generated from the company's high-throughput mass spectrometry-based platform. This capability is critical to selecting and functionally characterizing the most relevant targets for drug discovery and development. Ruhoff, director of informatics research, will lead the company's Odense, Denmark-based Proteomics and Laboratory Automation Software Engineering team in its efforts to enhance the company's mass spectrometry software  This article reads like a news release, or is otherwise written in an overly promotional tone.Please help [ rewrite this article] from a to be less promotional, per Wikipedia . . His work will be directed towards ensuring that MDS Proteomics maintains its long-term research objective to be at the forefront of developing novel bioinformatics solutions for proteomics. "Attracting exceptional colleagues like Hugues and Peder away from such prestigious institutions as the NCBI and Maersk Institute is testament to the bioinformatics capabilities and vision of fusing biology and informatics to fundamentally change drug discovery that MDS Proteomics has established. Our leadership position in bioinformatics for proteomics has made it easy to attract such key personnel," said Frank Gleeson, president and chief executive officer of MDS Proteomics. "We look forward to their contributions to our growing informatics team, which has made significant progress in building our capabilities." "With these additions, MDS Proteomics is in a position to complete the assembly of its informatics roadmap. This roadmap represents an unbroken in-silico pipeline for processing data from the human genome The human genome is the genome of Homo sapiens, which is composed of 24 distinct pairs of chromosomes (22 autosomal + X + Y) with a total of approximately 3 billion DNA base pairs containing an estimated 20,000–25,000 genes. all the way to the discovery of small molecule lead compounds for new therapeutics," said Chris Hogue, co-founder and chief informatics officer. In partnership with IBM (International Business Machines Corporation, Armonk, NY, www.ibm.com) The world's largest computer company. IBM's product lines include the S/390 mainframes (zSeries), AS/400 midrange business systems (iSeries), RS/6000 workstations and servers (pSeries), Intel-based servers (xSeries) , MDS Proteomics has deployed a powerful supercomputing infrastructure upon which components of the roadmap are being deployed. This infrastructure is capable of processing output from a network of ultra-sensitive mass spectrometers, located in both its Toronto and Odense facilities, and to identify and analyze proteins. The company has assembled a variety of hardware and software assets, many exclusively developed and used within MDS Proteomics, as well as a select few licensed third-party applications modified for the company's use. MDS Proteomics also contributes to the open-source development of the Biomolecular Interaction Network Database (BIND) software used by academic scientists to manage protein interaction information. Sicotte joins MDS Proteomics following a four-year tenure at the NCBI, where he focused on developing a variety of high-performance computational analysis tools. He contributed to such projects as Unigene, an experimental system for automatically partitioning GenBank sequences into a non-redundant set of gene-oriented clusters, and the Cancer Genome Anatomy Project (CGAP CGAP Consultative Group to Assist the Poorest CGAP Cancer Genome Anatomy Project CGAP Certified Government Auditing Professional CGAP Call Gapping Interval CGAP Commission on Government Accountability to the People (Florida) ), an interdisciplinary program (established and administered by the National Cancer Institute) developed to generate the information and technological tools needed to decipher the molecular anatomy Molecular anatomy is the investigation of the molecular changes of cells, tissues, and organs in a developing embryo. With this information, it is possible to determine potential activities of specific molecules, and using such observations, theories of gene function can be tested of the cancer cell. Sicotte earned his doctorate degree from Princeton University Princeton University, at Princeton, N.J.; coeducational; chartered 1746, opened 1747, rechartered 1748, called the College of New Jersey until 1896. Schools and Research Facilities in 1995. Ruhoff brings more than 10 years of experience in computational science | Computational science (or scientific computing) is the field of study concerned with constructing mathematical models and numerical solution techniques and using computers to analyze and solve scientific, social scientific and engineering problems. and engineering to MDS Proteomics. Most recently, he served as associate professor of applied mathematics at the Maersk McKinney Moller Institute for Production Technology at the University of Southern Denmark and director of the Maersk McKinney Moller Institute for Production Technology. Previously, he worked as an adjunct assistant professor in chemistry at Northwestern University. Ruhoff has published several key papers on a variety of computing research topics including algorithm development for mechanical simulations and computational chemistry. He earned his doctorate degree from Roskilde University in 1995 and his master's of science degree from Odense University. About MDS Proteomics A pioneer in the field of proteomic-enabled drug discovery, MDS Proteomics' goal is to significantly improve the productivity of the pharmaceutical industry in discovering and developing new medicines for the treatment of disease. The company has developed exceptional capabilities in proteomics systems, technology, supercomputing, drug design, screening and biology and is uniquely positioned to build an effective bridge between gene discovery and therapeutic development. This distinctive capability is being used in collaborations with pharmaceutical and biotechnology companies as well as for the development of the company's own product pipeline. In its proteomics facilities in Europe and North America, the company focuses on drug target discovery and validation for both antibody and small molecule therapeutics. MDS Proteomics is a majority-owned subsidiary majority-owned subsidiary A firm in which more than 50% of outstanding voting stock is owned by the parent company. of MDS Inc. For more information on MDS Proteomics, visit the company's website at http://www.mdsproteomics.com About MDS Inc. MDS Inc. (NYSE NYSE See: New York Stock Exchange :MDZ MDZ Mendez MDZ Moskauer Deutsche Zeitung (Moscow German newspaper) MDZ Maritime Defense Zone MDZ Musik Der Zukunft (music label & community) MDZ Mendoza, Mendoza, Argentina - El Plumerillo )(TSE See Tokyo Stock Exchange. TSE 1. See Tokyo Stock Exchange (TSE). 2. See Toronto Stock Exchange (TSE). :MDS) is an international health and life sciences company that is focused on fighting disease in numerous ways. Its products and services include: laboratory testing, imaging agents for nuclear medicine testing, sterilization sterilization Any surgical procedure intended to end fertility permanently (see contraception). Such operations remove or interrupt the anatomical pathways through which the cells involved in fertilization travel (see reproductive system). systems for medical and consumer products, research and clinical development services for planning and delivery of cancer treatment, analytical instruments to assist in the development of new drugs, and medical/surgical supplies. MDS employs more than 10,000 highly skilled people at its global operations on four continents. Detailed information about the company is available at the MDS Web site at www.mdsintl.com. |
|
||||||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion